BioSpace News Archive

Company adds Tim Cabral, former Veeva CFO, Priscilla Hung, president and COO of Guidewire Software, Tina Hunt, executive vice president of IDEXX Laboratories, Inc., and Marshall Mohr, executive vice president of global business services.

Mispro Biotech Services, North America’s leading contract vivarium organization with locations in all major U.S. biotech hubs, has announced expansion into Long Island City with a new preclinical vivarium research facility set to open in March.

Aurora Spine Corporation announced today that the first anterior cervical discectomy and fusion procedures were completed with its proprietary APOLLO TM Anterior Cervical Plate (ACP) system.

Monte Rosa Therapeutics, Inc. announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science, which aims to accelerate the discovery and development of novel covalent molecular glue degraders leveraging CoLDR.

Checkpoint Therapeutics, Inc. today announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody.

Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.

electroCore, Inc. announced three abstracts focusing on the possible mechanistic or clinical role of nVNS for the acute treatment of stroke will be presented at the American Heart Association’s 2022 International Stroke Conference, February 9th – 11th, 2022, in New Orleans, Louisiana.

Aeglea BioTherapeutics, Inc. today announced that it will host a Key Opinion Leader (KOL) and Patient Caregiver Webinar on Arginase 1 Deficiency on Thursday, February 3, 2022.

Purigen Biosystems Announces Commercial Distribution Agreement with the Institute of Applied Biotechnologies for Automated Ionic ® Purification System.

Arcturus Therapeutics Holdings Inc. today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.